Zynex Inc.  

(Public, OTCMKTS:ZYXI)   Watch this stock  
Find more results for OTC:ZYXI
-0.015 (-4.69%)
Feb 24 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.30 - 0.31
52 week 0.10 - 0.36
Open 0.31
Vol / Avg. 13,200.00/10,058.00
Mkt cap 9.59M
P/E     -
Div/yield     -
EPS -0.04
Shares 31.27M
Beta -2.13
Inst. own 0%

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin 14.67% -25.20%
Operating margin 17.15% -21.31%
EBITD margin - -17.67%
Return on average assets 46.98% -54.28%
Return on average equity - -
Employees 121 -
CDP Score - -


9990 Park Meadows Dr
LONE TREE, CO 80124-6739
United States - Map
+1-303-7034906 (Phone)
+1-800-4956695 (Fax)

Website links


Zynex, Inc. operates through the Electrotherapy and Pain Management Products segment. The Company conducts its business through its subsidiaries and the operating subsidiary is Zynex Medical, Inc. (ZMI). Its other subsidiaries include Zynex Monitoring Solutions, Inc. (ZMS) and Zynex Europe, ApS (ZEU). ZMI designs, manufactures and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. ZMS is in the process of developing its blood volume monitoring product for non-invasive cardiac monitoring. ZEU intends to focus on sales and marketing its products within the international marketplace, upon receipt of necessary regulatory approvals. It markets and sells Zynex-manufactured products and distributes private labeled products. Its products include NexWave, NeuroMove, InWave, Electrodes and Batteries. ZMI devices are intended for pain management to reduce reliance on drugs and medications.

Officers and directors

Thomas Sandgaard Chairman of the Board, President, Chief Executive Officer, Principal Financial Officer & Accounting Officer
Age: 56
Rick Luckenbill Vice President - Finance
David B. Mogill Vice President - Operations